Doctors are looking for ways to help men with advanced prostate cancer live longer. A new analysis looked at patients treated with PSMA-targeted radioligand therapy, a treatment that uses a radioactive tracer to find and kill cancer cells. The group studied nearly 5,000 patients who received this specific therapy. They wanted to know which patient traits predicted better survival times.
The results show that some factors make the disease harder to control. Men who had chemotherapy before starting this new treatment faced a higher risk of the cancer growing. Those with liver metastases, or cancer spread to the liver, also saw worse outcomes. Having lower red blood cell counts before treatment was another sign of poorer survival.
However, there were signs of hope. Patients with higher levels of a cancer marker called SUV before treatment did better. A big drop in the PSA blood test level after starting therapy also linked to longer life. These findings help doctors understand who is likely to benefit most from this powerful treatment.